Everything below concerns Agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
== Comparisons to vertebrates == This open system might appear to be inefficient compared to the closed circulatory systems of the vertebrates, but the two systems have very different demands placed on them. In vertebrates, the circulatory system is responsible for transporting oxygen to all the tissues and removing carbon dioxide from them. It is this requirement that establishes the level of performance demanded of the system. The efficiency of the vertebrate system is far greater than is needed for transporting nutrients, hormones, and so on; whereas in insects, exchange of oxygen and carbon dioxide occurs in the tracheal system. Hemolymph plays no part in the process in most insects. Only in a few insects living in low-oxygen environments are there hemoglobin-like molecules that bind oxygen and transport it to the tissues. Therefore, the demands placed upon the system are much lower. Some arthropods and most molluscs possess the copper-containing hemocyanin, however, for oxygen transport.
== Angle formulas == If e, f, g and h are the tangent lengths from the vertices A, B, C and D respectively to the points where the incircle is tangent to the sides of a tangential quadrilateral ABCD, then the angles of the quadrilateral can be calculated from
=== Reagents === Phenol: The phenol used for biochemistry comes as a water-saturated solution with Tris buffer, as a Tris-buffered 50% phenol, 50% chloroform solution, or as a Tris-buffered 50% phenol, 48% chloroform, 2% isoamyl alcohol solution (sometimes called "25:24:1"). Phenol is naturally somewhat water-soluble, and gives a fuzzy interface, which is sharpened by the presence of chloroform, and the isoamyl alcohol reduces foaming. Most solutions also have an antioxidant, as oxidized phenol damages the nucleic acids. For RNA purification, the pH is kept at around 4, which retains RNA in the aqueous phase preferentially. For DNA purification, the pH is usually near 7, at which point all nucleic acids are found in the aqueous phase. Chloroform: Chloroform is stabilized with small quantities of amylene or ethanol, because exposure of pure chloroform to oxygen and ultraviolet light produces phosgene gas. Some chloroform solutions come as pre-made a 96% chloroform, 4% isoamyl alcohol mixture that can be mixed with an equal volume of phenol to obtain the 25:24:1 solution. Isoamyl alcohol: Isoamyl alcohol may reduce foaming and ensure deactivation of RNases.
=== Single-molecule explanation === The adsorption of ensemble molecules on a surface or interface can be divided into two processes: adsorption and desorption. If the adsorption rate wins the desorption rate, the molecules will accumulate over time giving the adsorption curve over time. If the desorption rate is larger, the number of molecules on the surface will decrease over time. The adsorption rate is dependent on the temperature, the diffusion rate of the solute (related to mean free path for pure gas), and the energy barrier between the molecule and the surface. The diffusion and key elements of the adsorption rate can be calculated using Fick's laws of diffusion and the Einstein relation (kinetic theory). Under ideal conditions, when there is no energy barrier and all molecules that diffuse and collide with the surface get adsorbed, the number of molecules adsorbed
Sources: en.wikipedia.org
A trachea may be narrowed or compressed, usually a result of enlarged nearby lymph nodes; cancers of the trachea or nearby structures; large thyroid goitres; or rarely as a result of other processes such as unusually swollen blood vessels. Scarring from tracheobronchial injury or intubation; or inflammation associated with granulomatosis with polyangiitis may also cause a narrowing of the trachea (tracheal stenosis). Obstruction invariably causes a harsh breathing sound known as stridor. A camera inserted via the mouth down into the trachea, called bronchoscopy, may be performed to investigate the cause of an obstruction. Management of obstructions depends on the cause. Obstructions as a result of malignancy may be managed with surgery, chemotherapy or radiotherapy. A stent may be inserted over the obstruction. Benign lesions, such as narrowing resulting from scarring, are likely to be surgically excised. One cause of narrowing is tracheomalacia, which is the tendency for the trachea to collapse when there is increased external pressure, such as when airflow is increased during breathing in or out, due to decreased compliance. It can be due to congenital causes, or due to things that develop after birth, such as compression from nearby masses or swelling, or trauma. Congenital tracheomalacia can occur by itself or in association with other abnormalities such as bronchomalacia or laryngomalacia, and abnormal connections between the trachea and the oesophagus, amongst others.
Oral treatment: (brand names Daktarin in UK, Fungimin Oral Gel in Bangladesh): In 2010, the US Food and Drug Administration approved Oravig (miconazole) buccal tablets for the local treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older. External skin treatment (brand names Desenex and Zeasorb in US and Canada; Micatin, Monistat-Derm, Daktarin in India, UK, Australia, Belgium and the Philippines; Kalpanax in Indonesia; Daktar in Norway; Fungidal in Bangladesh; Decocort in Malaysia) (Note that Desenex originally contained not miconazole, but rather the fungistatic agents, undecylenic acid and zinc undecylenate, which were in the foot powder developed by the US government for troops during WWII.) Vaginal treatment (brand names Miconazex, Monistat, Femizol or Gyno-Daktarin in UK):
==== Medical conditions ==== Undiagnosed maternal celiac disease may cause a short duration of the breastfeeding period. Treatment with the gluten-free diet can increase its duration and restore it to the average value of the healthy women. Mothers with all types of diabetes mellitus normally use insulin to control their blood sugar, as the safety of other antidiabetic drugs while breastfeeding is unknown. Women with polycystic ovary syndrome, which is associated with some hormonal differences and obesity, may have greater difficulty with producing a sufficient supply to support exclusive breastfeeding, especially during the first weeks.
Sources: en.wikipedia.org
=== From end-of-life batteries === A few small companies are recycling spent batteries, focusing on recovering copper and cobalt. Some recover lithium carbonate alongside the compound Li2Al4(CO3)(OH)12⋅3H2O also.
=== Properties === Like other peptides belonging to the super-family of the ICK, GsMTx-4 is amphipathic. Therefore, GsMTx-4 is able to interact with the hydrophobic side of the lipid bilayer. It can insert itself into the membrane by binding to anionic and cationic groups based on hydrophobic and electrostatic interactions. However, GsMTx-4 has a weak selectivity for the anionic phospholipids over the zwitterionic phospholipids of the lipid bilayer compared to other ICK peptides. For all ICK blocker peptides, the dominating aromatic residues in the hydrophobic face are widely considered to promote the binding and adsorption of the peptide to the lipid bilayer by positively contributing to its bilayer partitioning energy. Compared with other ICK peptides, GsMTx-4 has a relatively high content of lysine residues, which causes the peptide to be more positively charged. This is important for its orientation and depth of the peptide penetration into the lipid bilayer.
Eicosanoids include prostaglandins that produce fever and the dilation of blood vessels associated with inflammation and leukotrienes that attract certain white blood cells (leukocytes). Common cytokines include interleukins that are responsible for communication between white blood cells; chemokines that promote chemotaxis; and interferons that have antiviral effects, such as shutting down protein synthesis in the host cell. Growth factors and cytotoxic factors may also be released. These chemicals recruit immune cells to the site of infection and promote the healing of any damaged tissue following the removal of pathogens.
Sub-ppb (parts per billion) levels of silica make it equally complex for both reactive and total silica analysis, making the choice of total silica test often preferred. Although particles and TOC are usually measured using on-line methods, there is significant value in complementary or alternative off-line lab analysis. The value of the lab analysis has two aspects: cost and speciation. Smaller UPW facilities that cannot afford to purchase on-line instrumentation often choose off-line testing. TOC can be measured in the grab sample at a concentration as low as 5 ppb, using the same technique employed for the on-line analysis (see on-line method description). This detection level covers the majority of needs of less critical electronic and all pharmaceutical applications. When speciation of the organics is required for troubleshooting or design purposes, liquid chromatography-organic carbon detection (LC-OCD) provides an effective analysis. This method allows for identification of biopolymers, humics, low molecular weight acids and neutrals, and more, while characterizing nearly 100% of the organic composition in UPW with sub-ppb level of TOC. Similar to TOC, SEM particle analysis represents a lower cost alternative to the expensive online measurements and therefore it is commonly a method of choice in less critical applications. SEM analysis can provide particle counting for particle size down to 50 nm, which generally is in-line with the capability of online instruments.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.